Amgen Withdraws Its Motion For Preliminary Injunction Against Hospira

Amgen v. Hospira (epoetin alfa)  •  U.S. Biosimilar Litigation News  •  Uncategorized

On July 12, 2017, Amgen filed a Notice of Withdrawal of its Motion for Preliminary Injunction.  As we previously reported, Amgen had filed an amended opening brief in support of its motion for preliminary injunction because of the Supreme Court’s decision in Sandoz v. Amgen. As we previously reported, Hospira filed a publicly-available redacted version of its responsive brief on July 6, 2017.

The deadline for Amgen’s reply was July 12, 2017.  Instead of filing a reply, Amgen filed a Notice of Withdrawal, noting that it was withdrawing its motion “[f]urther to the parties’ discussion with the Court during Oral Argument on June 28, 2017.”

Download PDF

Comments are closed.